Comment on

• Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.

  Bachot N, Revuz J, Roujeau JC. Bachot N, et al. Arch Dermatol. 2003 Jan;139(1):33-6. doi: 10.1001/archderm.139.1.33. Arch Dermatol. 2003. PMID: 12533161 Clinical Trial.
• Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.

  Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Trent JT, et al. Arch Dermatol. 2003 Jan;139(1):39-43. doi: 10.1001/archderm.139.1.39. Arch Dermatol. 2003. PMID: 12533162